The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lexeo Therapeutics Inc
NASDAQ:LXEO
|
US |
|
Indofood CBP Sukses Makmur Tbk PT
OTC:PNDFF
|
ID |
|
D
|
Denison Mines Corp
XMUN:IUQ
|
CA |
|
H
|
Henry Schein Inc
F:HS2
|
US |
|
C
|
China Life Insurance Co Ltd
XMUN:CHL
|
CN |
|
P
|
Prime Office A/S
CSE:PRIMOF
|
DK |
|
H
|
Haryana Capfin Ltd
BSE:532855
|
IN |
|
Cahya Mata Sarawak Bhd
OTC:CHYMF
|
MY |
|
D
|
DBS Group Holdings Ltd
SWB:DEVL
|
SG |
|
Mid-America Apartment Communities Inc
NYSE:MAA
|
US |
|
Swisscom AG
SIX:SCMN
|
CH |
|
Ferrovial SE
AEX:FER
|
NL |
|
O
|
Onyx Healthcare Inc
TPEX:6569
|
TW |
|
C
|
Campbell's Co
XHAM:CSC
|
US |
|
H
|
HCA Healthcare Inc
XMUN:2BH
|
US |
|
Paramount Global
NASDAQ:PSKY
|
US |
|
O
|
Old Dominion Freight Line Inc
F:ODF
|
US |
|
Kimia Farma Tbk PT
IDX:KAEF
|
ID |
|
Unity Software Inc
BMV:U
|
US |
|
S
|
Salesforce Inc
XMUN:FOO
|
US |
|
H
|
Heimar hf
ICEX:HEIMAR
|
IS |
Lexeo Therapeutics Inc (LXEO)’s 12-month stock price forecast through September 2027 has a consensus target of $20.4, implying 476% upside. The forecast is based on price targets from 12 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for LXEO is 20.4 USD with a low forecast of 15.15 USD and a high forecast of 31.5 USD.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more